Neuren (NEU) – ASX Announcement 12 November 2026 Neuren appoints Zita Peach to succeed Patrick Davies as Board Chair Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced that Ms Zita Peach has been appointed Chair of the Board following a carefully considered succession...
Zita Peach to succeed Patrick Davies as Board Chair
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Neuren Pharmaceuticals has appointed Zita Peach as the new Chair of the Board, succeeding Patrick Davies. The announcement highlights the company's commitment to growth and innovation in developing treatments for neurodevelopmental disorders. Zita expressed her enthusiasm for guiding Neuren through its next phase of growth and advancing its pipeline.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Q3 2026 DAYBUE net sales up 39%, full year guidance upgraded
- FDA grants Orphan Drug Designation for NNZ-2591 to treat HIE
- Trofinetide US patent protections extended to March 2041
- Pause in Trading
- Update - Dividend/Distribution - NEU
Later from Neuren Pharmaceuticals
- Initial Director's Interest Notice - Zita Peach
- Final Director's Interest Notice - P. Davies
- Acadia enters DAYBUE STIX distribution agreement in Japan
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals